By Josh Beckerman
Viatris shares fell to a 52-week low after the drug company said issues related to a India facility are expected to hurt 2025 total revenue by about $500 million.
The stock was recently down 14% to $9.63 and is down about 23% this year.
In December, the company received a warning letter and import alert from the Food and Drug Administration. The import alert affects 11 actively distributed products, including lenalidomide and everolimus, but the FDA made exceptions, subject to certain conditions, for four products based on shortage concerns.
Viatris said fourth-quarter results were strong and that full-year cash flow exceeded guidance. It reported fourth-quarter sales of $3.52 billion, down 8%.
The company plans to prioritize capital return in 2025, including $500 million to $650 million in share repurchases.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 27, 2025 13:20 ET (18:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。